Search
EHA-SWG Scientific Meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis
Dates: February 8-10, 2018
Location: Barcelona, Spain
Chair: MC Béné
Co-chair: G Zini
Organized by: EHA & the EHA Scientific Working Group on Diagnosis: Morphology and Flow Cytometry
After a successful first edition in 2015, this meeting returns to Barcelona on February 8-10, 2018.…
EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia
European Hematology Association (EHA) and European Society for Medical Oncology (ESMO) agreed to collaborate on the production of European Guidelines for different hematological malignancies.
Read moreHARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers
HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers: HARMONY Alliance is an unparalleled medicine offensive to battle blood cancers by using Big Data analyses.
Read moreProposal for an EU Regulation on Clinical Trials: A joint statement from non-commercial and commercial organisations
This statement outlines the areas of agreement within the health and research communities on where the Regulation will improve the research environment. Aspects of the Regulation that could be improved to further support clinical research are also highlighted.
Read moreDo generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.
The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.
‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda
On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- »